Glenmark Pharmaceuticals Ltd. plans to spin out its innovation business, which includes a basket of promising early to advanced new chemical entities (NCEs) and new biological entities (NBEs), into a new company based in the US.
The new unit, which received an in-principle go-ahead from the Glenmark board on Feb
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?